AR035679A1 - Sales farmaceuticamente aceptables del acido 3s,4ar,8ar-6-(((2s)-2-(carboxil)-4,4,-difluorpirrolidinil)metil)-1,2,3,4,4a,5,6,7,8,8a-decahidroisoquinolin-3-carboxilico, prodrogas de dichos compuestos; metodo para tratar desordenes neurologicos o neurodegenerativos utilizando dichas sales; uso de los - Google Patents
Sales farmaceuticamente aceptables del acido 3s,4ar,8ar-6-(((2s)-2-(carboxil)-4,4,-difluorpirrolidinil)metil)-1,2,3,4,4a,5,6,7,8,8a-decahidroisoquinolin-3-carboxilico, prodrogas de dichos compuestos; metodo para tratar desordenes neurologicos o neurodegenerativos utilizando dichas sales; uso de losInfo
- Publication number
- AR035679A1 AR035679A1 ARP020100030A ARP020100030A AR035679A1 AR 035679 A1 AR035679 A1 AR 035679A1 AR P020100030 A ARP020100030 A AR P020100030A AR P020100030 A ARP020100030 A AR P020100030A AR 035679 A1 AR035679 A1 AR 035679A1
- Authority
- AR
- Argentina
- Prior art keywords
- sales
- pharmaceutically acceptable
- compounds
- acid
- difluorpirrolidinil
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 208000025966 Neurological disease Diseases 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 230000000926 neurological effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 5
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Se describen y reivindican sales farmacéuticamente aceptables de los compuestos de fórmula (1) ó profármacos del mismo, seleccionadas dichas sales farmacéuticamente aceptables, del grupo constituido por la sal del ácido D-(-)-mandélico o la sal del ácido 1,5-naftalendisulfónico. Inclusive prodrogas de los compuestos mencionados y los objetos restantes mencionados en el título. Dichas sales son de aplicación como antagonistas selectivos de los receptores pertenecientes al subtipo iGluR5, de utilidad en el tratamiento de enfermedades neurodegenerativas; v. gr.: trastornos neurológicos sin efectos secundarios.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26001401P | 2001-01-05 | 2001-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035679A1 true AR035679A1 (es) | 2004-06-23 |
Family
ID=22987455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100030A AR035679A1 (es) | 2001-01-05 | 2002-01-04 | Sales farmaceuticamente aceptables del acido 3s,4ar,8ar-6-(((2s)-2-(carboxil)-4,4,-difluorpirrolidinil)metil)-1,2,3,4,4a,5,6,7,8,8a-decahidroisoquinolin-3-carboxilico, prodrogas de dichos compuestos; metodo para tratar desordenes neurologicos o neurodegenerativos utilizando dichas sales; uso de los |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1351955A1 (es) |
| JP (1) | JP2004520335A (es) |
| KR (1) | KR20030066797A (es) |
| CN (1) | CN1484642A (es) |
| AR (1) | AR035679A1 (es) |
| BR (1) | BR0116672A (es) |
| CA (1) | CA2431545A1 (es) |
| CZ (1) | CZ20031856A3 (es) |
| DZ (1) | DZ3460A1 (es) |
| EA (1) | EA200300770A1 (es) |
| EC (1) | ECSP034682A (es) |
| HR (1) | HRP20030544A2 (es) |
| HU (1) | HUP0302528A2 (es) |
| IL (1) | IL156138A0 (es) |
| MX (1) | MXPA03005981A (es) |
| NO (1) | NO20032973L (es) |
| NZ (1) | NZ525821A (es) |
| PE (1) | PE20020792A1 (es) |
| PL (1) | PL361934A1 (es) |
| SK (1) | SK8242003A3 (es) |
| TW (1) | TW591023B (es) |
| WO (1) | WO2002053561A1 (es) |
| ZA (1) | ZA200304311B (es) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5284957A (en) * | 1992-09-03 | 1994-02-08 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| EP1053234A1 (en) * | 1998-02-06 | 2000-11-22 | Smithkline Beecham Plc | Salts of paroxetine |
| GB9908175D0 (en) * | 1999-04-09 | 1999-06-02 | Lilly Co Eli | Method of treating neurological disorders |
| HRP20020013A2 (en) * | 1999-07-06 | 2003-08-31 | Lilly Co Eli | SELECTIVE iGluR<SUB>5</SUB> RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
-
2001
- 2001-12-20 HU HU0302528A patent/HUP0302528A2/hu unknown
- 2001-12-20 HR HR20030544A patent/HRP20030544A2/hr not_active Application Discontinuation
- 2001-12-20 PL PL01361934A patent/PL361934A1/xx not_active Application Discontinuation
- 2001-12-20 SK SK824-2003A patent/SK8242003A3/sk unknown
- 2001-12-20 EP EP01995980A patent/EP1351955A1/en not_active Withdrawn
- 2001-12-20 NZ NZ525821A patent/NZ525821A/en unknown
- 2001-12-20 JP JP2002554680A patent/JP2004520335A/ja active Pending
- 2001-12-20 KR KR10-2003-7008977A patent/KR20030066797A/ko not_active Withdrawn
- 2001-12-20 MX MXPA03005981A patent/MXPA03005981A/es unknown
- 2001-12-20 CA CA002431545A patent/CA2431545A1/en not_active Abandoned
- 2001-12-20 EA EA200300770A patent/EA200300770A1/ru unknown
- 2001-12-20 WO PCT/US2001/044715 patent/WO2002053561A1/en not_active Ceased
- 2001-12-20 BR BR0116672-7A patent/BR0116672A/pt not_active IP Right Cessation
- 2001-12-20 CN CNA018217508A patent/CN1484642A/zh active Pending
- 2001-12-20 IL IL15613801A patent/IL156138A0/xx unknown
- 2001-12-20 CZ CZ20031856A patent/CZ20031856A3/cs unknown
- 2001-12-20 DZ DZ013460A patent/DZ3460A1/fr active
-
2002
- 2002-01-04 AR ARP020100030A patent/AR035679A1/es not_active Application Discontinuation
- 2002-01-04 PE PE2002000003A patent/PE20020792A1/es not_active Application Discontinuation
- 2002-01-04 TW TW091100071A patent/TW591023B/zh not_active IP Right Cessation
-
2003
- 2003-06-02 ZA ZA200304311A patent/ZA200304311B/en unknown
- 2003-06-27 NO NO20032973A patent/NO20032973L/no not_active Application Discontinuation
- 2003-07-03 EC EC2003004682A patent/ECSP034682A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DZ3460A1 (fr) | 2002-07-11 |
| CZ20031856A3 (cs) | 2003-09-17 |
| CA2431545A1 (en) | 2002-07-11 |
| PL361934A1 (en) | 2004-10-18 |
| TW591023B (en) | 2004-06-11 |
| BR0116672A (pt) | 2003-09-23 |
| NO20032973D0 (no) | 2003-06-27 |
| KR20030066797A (ko) | 2003-08-09 |
| ECSP034682A (es) | 2003-08-29 |
| JP2004520335A (ja) | 2004-07-08 |
| HRP20030544A2 (en) | 2004-08-31 |
| WO2002053561A1 (en) | 2002-07-11 |
| MXPA03005981A (es) | 2003-09-10 |
| NZ525821A (en) | 2004-07-30 |
| SK8242003A3 (en) | 2004-01-08 |
| EP1351955A1 (en) | 2003-10-15 |
| IL156138A0 (en) | 2003-12-23 |
| ZA200304311B (en) | 2004-09-02 |
| NO20032973L (no) | 2003-06-27 |
| CN1484642A (zh) | 2004-03-24 |
| PE20020792A1 (es) | 2002-09-06 |
| EA200300770A1 (ru) | 2003-10-30 |
| HUP0302528A2 (hu) | 2003-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP034640A (es) | Derivados de feniletenilo o feniletinilo como antagonistas del receptor del glutamato | |
| ECSP034744A (es) | Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos | |
| CR9910A (es) | Antagonistas del receptor 3 de la histamina | |
| BRPI0415657A (pt) | derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c | |
| CY1111977T1 (el) | Παραγωγα πιπεριδιν-4-υλ-πυριδαζιν-3-υλαμινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2 | |
| BR0104834A (pt) | Moduladores de receptores de glucocorticóides | |
| AR047992A1 (es) | Diaminopirimidinas como antagonistas de p2x3 y p2x2/3 | |
| UY29710A1 (es) | Benzimidazoles tricíclicos y su uso como moduladores de receptores metabotrópicos de glutamato | |
| PE20010205A1 (es) | Derivados 3-sustituido de 2-carboxiciclopropil glicina como agonistas de glutamato | |
| EA200600190A1 (ru) | Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона | |
| GT199800021A (es) | Utilizacion de antagonistas de los receptores de canabinoides centrales para la preparacion de medicamentos. | |
| EA201170473A1 (ru) | Морфинановые соединения | |
| AR028824A1 (es) | Compuestos antagonistas npy-5 y su uso en la manufactura de medicamentos. | |
| AR040278A1 (es) | Ligandos del receptor de glucocorticoides para el tratamiento de trastornos metabolicos | |
| ECSP056134A (es) | Derivados de quinuclidina que se enlazan con los receptores muscarínicos m3 | |
| DE60120077D1 (de) | Modulatoren des Glucocorticoid-Rezeptors | |
| AR029373A1 (es) | Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas | |
| ES2156287T3 (es) | Derivados de difenilmetilen piperidina. | |
| CL2004000769A1 (es) | Compuestos derivados del acido [2-(8,9-dioxo-2,6-diazabiciclo [5,2,o]non-1-(7)-en-2-il) alquil]fosfonico, antagonistas del receptor n-metil-d-aspartato (nmda); procedimiento de preparacion; composicion farmaceutica; y su uso para tratar desordenes va | |
| PE20050141A1 (es) | DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA | |
| BRPI0417520A (pt) | 1h-pirrolo[3,2-b, 3,2-c, e 2,3-c]piridina-2-carboxamidas substituìdas e análogos relatados como inibidores de caseìna cinase i-epsilon | |
| DK1458393T3 (da) | Substituerede diketopiperaziner som oxytocinantagonister | |
| UY26919A1 (es) | Derivados de la quinazolina como antagonistas adrenérgicos alfa - 1 | |
| ES2092646T3 (es) | Metanoantracenos como antagonistas de dopamina. | |
| ECSP056192A (es) | 3-fluoro-piperidinas como antagonistas de nmda/nr2b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FA | Abandonment or withdrawal |